Therefore, future studies should enroll a larger sample size to validate whether CD4+ Tcm MMP-Low and SCMM-CD3+CD4+ T cells can serve as effective biomarkers for reflecting SLE disease activity. The gene discussed is CD4; the disease is systemic lupus erythematosus.